BridgeMD
A Phase 2b Study of MK-6024 in Adults with Precirrhotic Nonalcoholic Steatohepatitis
EU CTIS ID: 2022-502647-35-00
What this study is testing
1. To evaluate the effect of efinopegdutide versus placebo on the proportion of individuals with NASH resolution without worsening of fibrosis at Week 52. 2. To evaluate the safety and tolerability of efinopegdutide.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Histologic confirmation of NASH based on liver biopsy. Histologic criteria for study entry include: • Nonalcoholic fatty liver disease (NAFLD) Activity Score ≥4 with a score ≥1 point in each component (steatosis, ballooning, and lobular inflammation), AND • NASH Clinical Research Network (CRN) fibrosis score indicative of Stage 2 or 3.
- No history of Type 2 diabetes mellitus (T2DM) OR a history of T2DM controlled by diet or stable doses of antihyperglycemic agents (AHAs)
- Participants in South Korea are eligible between the ages of 19 to 80 years of age (inclusive)
You likely can't join if
- History of liver disease other than NASH
- History or evidence of cirrhosis
- History of pancreatitis
- History of Type 1 Diabetes Mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatectomy
- History of bariatric surgery ≤5 years before study participation
- Has significant systemic or major illnesses, including recent events (≤6 months before study entry) of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or transient ischemic attack
The study team makes the final eligibility decision.
Where it's taking place
- Singapore
- Taiwan
- China
- South Africa
- United Kingdom
- Canada
- Japan
- Turkey
- Korea, Democratic People's Republic of
- Hong Kong
- Israel
- Colombia
- Puerto Rico
- Chile
- Mexico
- Peru
- Thailand
- United States
- Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Singapore; Taiwan; China; South Africa; United Kingdom; Canada and 13 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.